23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Twist Bioscience Corporation › 2025-2026

Twist Bioscience Corporation 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Twist Bioscience Corporation’s Form 8-K, filed February 6, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 278Asset managers, any item
  • 1,483Fund votes
  • February 5, 2026Meeting date

Results at a glance

Meeting of February 5, 2026: 5 items on Twist Bioscience Corporation’s Form 8-K, filed February 6, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 2 directors (19.5%, 15.9% against); 1 say-on-pay vote (76.4% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Twist Bioscience Corporation in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Twist Bioscience Corporation

These tallies are Twist Bioscience Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed February 6, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Twist Bioscience Corporation — official shareholder meeting results, meeting held February 5, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Keith Crandell 40,500,506---- 9,805,1975,954,803 81%Passed (calculated)—
Elect Director: Jan Johannessen 42,319,597---- 7,986,1065,954,803 84%Passed (calculated)—
Elect Director: Trynka Shineman Blake 50,217,493---- 88,2105,954,803 99.8%Passed (calculated)—
2. Non-Binding, Advisory Vote to Approve the Compensation of the Company's Named Executive Officers ("NEOs") 38,430,67311,842,36732,663 --5,954,803 76%Approved—
3. Ratification of Appointment of Independent Registered Accounting Firm 56,220,55118,17021,785 ---- 99.9%Approved—

Source: Twist Bioscience Corporation, Form 8-K, filed with the SEC on February 6, 2026 — read the filing on EDGAR.

How asset managers voted at the Twist Bioscience Corporation 2025-2026 meeting

278 asset managers disclosed a vote on at least one Twist Bioscience Corporation item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jan Johannessen

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD
FOR: 42,319,597WITHHELD: 7,986,106
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Election of Class II Directors: Jan Johannessen

Twist Bioscience Corporation’s own tally for this item (“Elect Director: Jan Johannessen”): 42,319,597 for, 7,986,106 withheld, per its Form 8-K filed February 6, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 18,709,055 for, 2,803,500 withheld, 261,295 abstained.

FOR
FOR: 18,709,055ABSTAIN: 261,295WITHHOLD: 2,803,500
Largest asset managers voting on “Election of Class II Directors: Jan Johannessen” at Twist Bioscience Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust6,627,9170 00For
Vanguard5,240,0510 0550For
BlackRock1,398,0720 00For
Thrivent00 01,353,808Withhold
WILLIAM BLAIR FUNDS1,163,6070 00For
Invesco799,1050 00For
Bridge Builder Trust693,5790 12,0390For
State Street672,2510 0705For
American Century00 0664,961Withhold
Charles Schwab546,5710 00For
Fidelity289,0940 00For
TIAA284,1990 00For
PROFESSIONALLY MANAGED PORTFOLIOS00 191,7200Abstain
Equitable88,1800 044,531Mixed
AMERICAN BEACON FUNDS132,1630 00For
Allspring00 0119,907Withhold
Victory Capital00 0114,743Withhold
MassMutual103,1250 00For
AIG/SunAmerica00 0102,155Withhold
QUANTITATIVE MASTER SERIES LLC100,8230 00For
Direxion Shares ETF Trust00 084,583Withhold
Lincoln Financial43,5880 039,033Mixed
OPTIMUM FUND TRUST80,1060 00For
ARK Venture Fund68,6790 00For
Neuberger Berman66,7540 00For

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Elect Director: Keith Crandell

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 40,500,506WITHHELD: 9,805,197
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Election of Class II Directors: Keith Crandell

Twist Bioscience Corporation’s own tally for this item (“Elect Director: Keith Crandell”): 40,500,506 for, 9,805,197 withheld, per its Form 8-K filed February 6, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 17,756,438 for, 3,755,147 withheld, 262,265 abstained.

FORWITHHOLD
FOR: 17,756,438ABSTAIN: 262,265WITHHOLD: 3,755,147
Largest asset managers voting on “Election of Class II Directors: Keith Crandell” at Twist Bioscience Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust6,627,9170 00For
Vanguard5,240,0510 0550For
BlackRock1,398,0720 00For
Thrivent00 01,353,808Withhold
WILLIAM BLAIR FUNDS1,163,6070 00For
Invesco00 0799,105Withhold
Bridge Builder Trust693,5790 12,0390For
State Street672,2510 0705For
American Century00 0664,961Withhold
Charles Schwab546,5710 00For
Fidelity289,0940 00For
TIAA284,1990 00For
PROFESSIONALLY MANAGED PORTFOLIOS00 191,7200Abstain
Equitable88,1800 044,531Mixed
AMERICAN BEACON FUNDS132,1630 00For
Allspring00 0119,907Withhold
Victory Capital00 0114,743Withhold
MassMutual00 0103,125Withhold
AIG/SunAmerica00 0102,155Withhold
QUANTITATIVE MASTER SERIES LLC100,8230 00For
Direxion Shares ETF Trust00 084,583Withhold
Lincoln Financial43,5880 039,033Mixed
OPTIMUM FUND TRUST80,1060 00For
ARK Venture Fund68,6790 00For
Neuberger Berman66,7540 00For

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Elect Director: Trynka Shineman Blake

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 50,217,493WITHHELD: 88,210
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Election of Class II Directors: Trynka Shineman Blake

Twist Bioscience Corporation’s own tally for this item (“Elect Director: Trynka Shineman Blake”): 50,217,493 for, 88,210 withheld, per its Form 8-K filed February 6, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 21,764,446 for, 9,404 withheld.

FOR
FOR: 21,764,446WITHHOLD: 9,404
Largest asset managers voting on “Election of Class II Directors: Trynka Shineman Blake” at Twist Bioscience Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust6,627,9170 00For
Vanguard5,240,6010 00For
BlackRock1,398,0720 00For
Thrivent1,353,8080 00For
WILLIAM BLAIR FUNDS1,163,6070 00For
Invesco799,1050 00For
Bridge Builder Trust705,6180 00For
State Street672,9560 00For
American Century664,9610 00For
Charles Schwab546,5710 00For
Fidelity289,0940 00For
TIAA284,1990 00For
PROFESSIONALLY MANAGED PORTFOLIOS191,7200 00For
Equitable132,7110 00For
AMERICAN BEACON FUNDS132,1630 00For
Allspring119,9070 00For
Victory Capital114,7430 00For
MassMutual103,1250 00For
AIG/SunAmerica102,1550 00For
QUANTITATIVE MASTER SERIES LLC100,8230 00For
Direxion Shares ETF Trust84,5830 00For
Lincoln Financial82,6210 00For
OPTIMUM FUND TRUST80,1060 00For
ARK Venture Fund68,6790 00For
Neuberger Berman66,7540 00For

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Non-Binding, Advisory Vote to Approve the Compensation of the Company's Named Executive Officers ("NEOs")

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

76% Approved · of votes cast

FOR 76%AGAINST
FOR: 38,430,673AGAINST: 11,842,367

Prior year: 97.6% for (February 4, 2025 meeting) ▼ 21.2 pts

Details: description as filed, official tally, votes by 278 asset managers

Description as filed by funds: To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers, as described in the Proxy Statement under "Executive Compensation."

Twist Bioscience Corporation’s own tally for this item (“2. Non-Binding, Advisory Vote to Approve the Compensation of the Company's Named Executive Officers ("NEOs")”): 38,430,673 for, 11,842,367 against — passed, per its Form 8-K filed February 6, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two — Non-Binding, Advisory Vote to Approve the Compensation of the Company's Named Executive Officers ("NEOs") The Company's stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of the Company's NEOs, by the following votes:”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 75 asset managers voting on “To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Offic” at Twist Bioscience Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust6,627,9170 00For
Vanguard2,551,9212,688,679 00Mixed
BlackRock1,398,0720 00For
Thrivent01,353,808 00Against
WILLIAM BLAIR FUNDS1,163,6070 00For
Invesco0799,105 00Against
Bridge Builder Trust693,57912,039 00For
State Street671,6741,282 00For
American Century0664,961 00Against
Charles Schwab546,5710 00For
Fidelity289,0940 00For
TIAA284,1990 00For
PROFESSIONALLY MANAGED PORTFOLIOS0191,720 00Against
Equitable88,18044,531 00Mixed
AMERICAN BEACON FUNDS132,1630 00For
Allspring0119,907 00Against
Victory Capital0114,743 00Against
MassMutual0103,125 00Against
AIG/SunAmerica0102,155 00Against
QUANTITATIVE MASTER SERIES LLC100,8230 00For
Direxion Shares ETF Trust084,583 00Against
Lincoln Financial42,30040,321 00Mixed
OPTIMUM FUND TRUST80,1060 00For
ARK Venture Fund68,6790 00For
Neuberger Berman66,7540 00For

Fund voting reports, all 75 managers: 15,075,475 for, 6,688,968 against, 9,404 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 220 asset managers voting on “To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Offic” at Twist Bioscience Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC4,562,8830 00For
Artisan4,219,9300 00For
Amova Asset Management Co., Ltd.01,902,829 00Against
BlackRock1,810,88720,016 00For
Thrivent01,361,830 00Against
State Street1,275,1909,548 00For
First Light Asset Management, LLC1,131,2810 00For
Invesco01,066,114 00Against
BAILLIE GIFFORD & CO LTD845,2220 00For
American Century0735,753 00Against
Freshford Capital Management, LLC616,4750 00For
Charles Schwab546,9820 00For
Vanguard447,28158,677 00Mixed
ARK Investment Management LLC458,1880 00For
Soleus Capital Management, L.P.398,0640 00For
JENNISON ASSOCIATES LLC361,9350 00For
Aberdeen308,1160 00For
Baillie Gifford Investment Management (Europe) Ltd293,5830 00For
Nuveen290,5560 00For
Northern Trust263,27212,677 00For
GEODE CAPITAL MANAGEMENT, LLC257,3460 00For
OSTERWEIS CAPITAL MANAGEMENT INC0254,798 00Against
Wellington248,0970 00For
JUPITER ASSET MANAGEMENT LTD0243,669 00Against
PICTET ASSET MANAGEMENT SA0212,381 00Against

Institutional-manager reports, all 220 managers: 19,747,553 for, 7,993,364 against, 85 abstained, 2,406 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 56,220,551AGAINST: 18,170

Prior year: 100.0% for (February 4, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2026.

Twist Bioscience Corporation’s own tally for this item (“3. Ratification of Appointment of Independent Registered Accounting Firm”): 56,220,551 for, 18,170 against — passed, per its Form 8-K filed February 6, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered accounting firm for the fiscal year ending September 30, 2026, by the following votes:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 21,764,446 for, 9,404 abstained.

FOR
FOR: 21,764,446ABSTAIN: 9,404
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Twist Bioscience Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust6,627,9170 00For
Vanguard5,240,6010 00For
BlackRock1,398,0720 00For
Thrivent1,353,8080 00For
WILLIAM BLAIR FUNDS1,163,6070 00For
Invesco799,1050 00For
Bridge Builder Trust705,6180 00For
State Street672,9560 00For
American Century664,9610 00For
Charles Schwab546,5710 00For
Fidelity289,0940 00For
TIAA284,1990 00For
PROFESSIONALLY MANAGED PORTFOLIOS191,7200 00For
Equitable132,7110 00For
AMERICAN BEACON FUNDS132,1630 00For
Allspring119,9070 00For
Victory Capital114,7430 00For
MassMutual103,1250 00For
AIG/SunAmerica102,1550 00For
QUANTITATIVE MASTER SERIES LLC100,8230 00For
Direxion Shares ETF Trust84,5830 00For
Lincoln Financial82,6210 00For
OPTIMUM FUND TRUST80,1060 00For
ARK Venture Fund68,6790 00For
Neuberger Berman66,7540 00For

Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).

Largest Twist Bioscience Corporation shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,311,704 shares outstanding at the time of that meeting.

Fund voting reports: top Twist Bioscience Corporation shareholders by shares voted on “To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named…”, 2025-2026
#Asset manager % of shares outstanding
1ARK ETF Trust 10.81%
2Vanguard 8.55%
3BlackRock 2.28%
4Thrivent 2.21%
5WILLIAM BLAIR FUNDS 1.90%
6Invesco 1.30%
7Bridge Builder Trust 1.15%
8State Street 1.10%
9American Century 1.08%
10Charles Schwab 0.89%
Institutional-manager reports: top Twist Bioscience Corporation shareholders by shares voted on “To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named…”, 2025-2026
#Asset manager % of shares outstanding
1WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 7.44%
2Artisan 6.88%
3Amova Asset Management Co., Ltd. 3.10%
4BlackRock 2.99%
5Thrivent 2.22%
6State Street 2.10%
7First Light Asset Management, LLC 1.85%
8Invesco 1.74%
9BAILLIE GIFFORD & CO LTD 1.38%
10American Century 1.20%

Reported Twist Bioscience Corporation holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Twist Bioscience Corporation holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group5,776,198 9.42%Form 13F, quarter ended March 31, 2026
BlackRock5,554,362 9.06%Form 13F, quarter ended March 31, 2026
Artisan Partners Asset Management Inc.4,802,017 7.83%Schedule 13G, filed August 13, 2026
State Street3,670,682 5.99%Form 13F, quarter ended March 31, 2026
T. Rowe Price Associates, Inc.3,634,470 5.93%Schedule 13G, filed August 14, 2026
ARK Investment Management LLC3,385,850 5.52%Schedule 13G, filed September 8, 2026
EdgePoint Investment Group Inc.2,521,635 4.11%Schedule 13G, filed August 14, 2026
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC2,174,594 3.55%Schedule 13G, filed August 11, 2026
Invesco2,171,898 3.54%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)1,889,945 3.08%Form 13F, quarter ended March 31, 2026

Percentages above are of 61,311,704 shares outstanding, as reported by Twist Bioscience Corporation on its Form 10-Q dated January 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Twist Bioscience Corporation's shareholder meeting held February 5, 2026, in the 2025-2026 proxy season, 278 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,483 separate fund positions. On the most widely held item on that ballot — To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named… — Twist Bioscience Corporation's filing reports the proposal as approved, with 76% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Twist Bioscience Corporation's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on February 6, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Twist Bioscience Corporation’s 10-Q dated January 27, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Twist Bioscience Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Twist Bioscience (TWST) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/twist-bioscience-corp/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.